Physician profile
Fernando Pino
NPI 1336151794
$1,200.70
in general payments reported to CMS, 2019-2025
15 companies · $281 in 2025
The $281 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.94 · 2020: $20.15 · 2022: $46.54 · 2023: $188 · 2024: $646 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $257.71 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $201.05 | 2022-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $156.07 | 2019-2025 | Invega Sustenna |
| Lundbeck LLC | $155.37 | 2023-2025 | Rexulti |
| Tris Pharma INC | $86.78 | 2024-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $67.65 | 2023-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.01 | 2023-2025 | Caplyta |
| Tempus Ai, INC | $40.95 | 2024 | |
| Abbvie INC. | $37.92 | 2023 | |
| Corium, LLC | $33.15 | 2025 | Azstarys |
| Indivior INC. | $25.01 | 2024 | Perseris |
| Almatica Pharma LLC | $24.50 | 2024 | Loreev Xr |
| Alkermes, INC. | $22.22 | 2022 | |
| Sunovion Pharmaceuticals INC. | $20.15 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $15.16 | 2024 | Uzedy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Pino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.